Baird Maintains Outperform on Blueprint Medicines, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains an Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $112 to $127.
August 02, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Blueprint Medicines and raises the price target from $112 to $127.
The raised price target and maintained Outperform rating by a reputable analyst is likely to positively impact investor sentiment and drive short-term price appreciation for Blueprint Medicines.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100